Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD)

Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD)

Mustafa Acar,1 Prabhjot Juneja,2 Malcolm Handel1 1Janssen-Cilag Pty Ltd, Sydney, NSW, Australia; 2Prospection Pty Ltd., Sydney, NSW, Australia Introduction: To describe the persistence of treatment with subcutaneous tumor necrosis factor inhibitors (TNFi) adalimumab, etanercept, and golimumab in imm...

Full description

Bibliographic Details
Main Authors: Acar M, Juneja P, Handel M
Format: Article
Language:English
Published: Dove Medical Press 2018-11-01
Series:Open Access Rheumatology : Research and Reviews
Subjects:
tumor necrosis factor inhibitor
arthritis
psoriatic
rheumatoid arthritis
ankylosing spondylitis
treatment persistence
Online Access:https://www.dovepress.com/treatment-persistence-of-subcutaneous-tnf-inhibitors-among-australian--peer-reviewed-article-OARRR

Internet

https://www.dovepress.com/treatment-persistence-of-subcutaneous-tnf-inhibitors-among-australian--peer-reviewed-article-OARRR

Similar Items